Panax ginseng C.A.Mey. has been widely consumed as food/diet supplements from natural sources, and its therapeutic properties have also aroused widespread concern. Therapeutic properties of Panax ginseng C.A.Mey. such as anti-inflammatory, ameliorating chronic inflammation, enhancing the immunity, resisting the oxidation again, and regulating the glucose and lipid metabolism have been widely reported. Recent years, lots of interesting studies have reported the potential use of Panax ginseng C.A.Mey. in the management of DKD. DKD has become the leading cause of end-stage renal disease worldwide, which increases the risk of premature death and poses a serious financial burden. Although DKD is somehow controllable with different drugs such as Angiotensin-Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB) and lowering-glucose agents, modern dietary changes associated with DKD have facilitated research to assess the preventive and therapeutic merits of diet supplements from natural sources as medicine including Panax ginseng C.A.Mey. Findings from many scientific evidences have suggested that Panax ginseng C.A.Mey. can relieve the pathological status in cellular and animal models of DKD. Moreover, a few studies showed that alleviation of clinical phenotype such as reducing albuminuria, serum creatinine and renal anemia in DKD patients after application or consumption of Panax ginseng C.A.Mey.. Therefore, this review aims to discuss the effectiveness of Panax ginseng C.A.Mey. as medicine for targeting pathological phenotypes in DKD from a pharmacological perspective. This review will provide new insights into the potential understanding use of Panax ginseng C.A.Mey. in the management of DKD in clinical settings.

Keywords: ginseng, diet supplements, diabetic kidney disease, pathological phenotypes, pharmacological perspective -3 -
INTRODUCTION

An ancient proverb states “Food/Diet Supplements from Natural Sources as Medicine”, and this adage is supported by the results of the Global Burden of Disease (GBD) Study 2017, which showed that dietary risk factors and poor diets contributed to 11 million premature deaths and 255 million disability-adjusted life-years. Another study reported that poor diets (such as ultra-processed foods, soft drinks, poultry or fish nuggets and salty snacks) are associated with an increased risk of diabetes and its complications (Srour et al., 2020). These staggering data show that suboptimal diets may lead to more deaths and highlight the “Food/Diet Supplements from Natural Sources as Medicine” as a strategy for improving poor diet, combating the burden of non-communicable diseases, including diverse kidney diseases (KD). “Food/Diet Supplements from Natural Sources as Medicine” could potentially have positive effects on kidney protection (KP) (Stenvinkel et al., 2020).

Panax ginseng C.A.Mey. has been widely consumed as food/diet supplements from natural sources, and its therapeutic properties have also aroused widespread concern (Figure 1) (Fan et al., 2020a). Therapeutic properties of Panax ginseng C.A.Mey. such as anti-inflammatory, altering the composition and metabolism of the microbiota, ameliorating chronic inflammation, enhancing the immunity, resisting the oxidation again, and regulating the glucose and lipid metabolism have been widely reported (Cao et al., 2019; Jang et al., 2019; Liu et al., 2019, 2020; Xue et al., 2019; Huang et al., 2020; Quan et al., 2020; Xu et al., 2020). Intriguing new data suggest that Panax ginseng C.A.Mey. could minimize renal injury by inhibiting oxidative stress, inflammatory responses, epithelial-mesenchymal transition, and fibrosis (Liu et al., 2020; Shi et al., 2020; Xie et al., 2020; Zhu et al., 2020; Li et al., 2021). This finding is pertinent to the pathologic phenotype of KD, which is characterized by features of destruction of the glomerular filtration barrier involving podocyte, basement membrane and endotheliocyte (Thomas et al., 2015). Further, these pathological changes could contribute to the deterioration of renal function such as proteinuria, increased serum creatinine, changes in glomerular filtration rate and renal anemia (Thomas et al., 2015). Clinically, Panax ginseng C.A.Mey. also has been shown to possess beneficial effects in the treatment of KP (Lang et al., 1998; Zhao et al., 2007).

Over the last decade, promising advancements have been made in the mechanisms and clinical outcomes of Panax ginseng C.A.Mey. on KD. Here, we are focusing on a discussion of Panax ginseng C.A.Mey. associating with KP. In addition, the possible active ingredients within Panax ginseng C.A.Mey. responsible for KP are elucidated. Table 1 summaries the kidney protection performances of ginsenosides in preclinical studies. These contents will be overviewed in detail in the following sections.

POTENTIAL BIO-ACTIVE COMPOUNDS OF PANAX GINSENG C.A.MEY. IN KIDNEY PROTECTION

At present, more than 150 monomers have been identified and isolated from the roots, stems, leaves, flowers, and fruits of Panax ginseng C.A.Mey., of which more than 30 ginsenoside monomers have been identified in Panax ginseng C.A.Mey. as effective ingredients (Chang-Xiao and Pei-Gen, 1992; Nah, 1997; Wong et al., 2015). Panax ginseng C.A.Mey. triol (PT) saponins are also the main representative components of ginsenosides Rgl, Rd, Rb1, which have a high content of active parts and strong activity (Wong et al., 2015). Here, the compounds having potential beneficial effects on kidney protective function are highlighted (Figure 2).

PROTECTIVE EFFECT OF PANAX GINSENG C.A.MEY. ON RENAL INNATE CELLS

The preponderance of evidence supports the obvious: Panax ginseng C.A.Mey. can relieve renal innate cells damage and has a protective effect of Panax ginseng C.A.Mey. on the glomerular filtration barrier. The kidney filtration barrier is surrounded by three layers: 1) a fenestrated endothelium, 2) a basement membrane, and 3) the podocytes. The glomerular filtration barrier can effectively prevent albumin and larger molecular weight substances in the plasma from entering the urine. The changes in the structure and function of the glomerular filtration barrier caused by various reasons are the pathophysiological basis of proteinuria (Blaine and Dylewski, 2020). Studies have shown that proteinuria reflects not only kidney damage but also an independent risk factor leading to the progression of kidney disease (Webster et al., 2017). Therefore, understanding the molecular structure and function of the glomerular filtration barrier are essential for delaying the progression of KD. Here, we highlight Panax ginseng C.A.Mey. on kidney protection in the kidney filtration barrier and innate renal cells.
TABLE 1 | Ginsenosides tested in animal or cellular studies for human kidney-related diseases.

| Model                                      | Ginsenosides                             | Animal/cell type               | Therapeutic mechanism                                                                 |
|--------------------------------------------|------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------|
| Targeting podocytes                        | Panax notoginseng saponins              | STZ rats and podocyte cells    | Inhibiting the podocyte cell apoptosis via reducing oxidative stress                    |
|                                            | Panax notoginseng saponins              |                                | Increasing the mRNA expression of nephrin, α3β1 integrin proteins                  |
| Targeting glomerular basement membrane nephritis | Rg1                                      | STZ rats, podocyte cells and basement membrane cells | Inhibitingglomerular basement membrane nephritis through regulating the nuclear factor E2-related factor 2 (Nrf2) pathway |
|                                            | Rg1                                      |                                | Supressing inflammation, oxidative stress via activating Nrf2 signal pathway          |
| Targeting glomerular endothelial barrier    | Rg1                                      | HUVEC                          | Reducing the heparanase mRNA and transendothelial resistance and transendothelial albumin pass rate |
| Targeting glomerular mesangial cells        | Rb1                                      | HGMC                           | Inhibition of the TGF-β/Smad signaling pathway and glycosylation end products       |
|                                            | Rb1                                      |                                | Promoting the proliferation of mesangial cells, inhibiting cell apoptosis and Caspase-3 expression |
|                                            | Rb1                                      |                                | Reducing the number of apoptotic cells, the activity of extracellular lactate dehydrogenase and block the cell cycle of human glomerular mesangial cells in G1 phase, and downregulate the mRNA and protein expression level of Cyclin-dependent kinase 4 (CDK4) |
| Targeting renal tubular cells              | Rb1                                      | HK-2                           | Activating the PI3K/AKT pathway and inhibiting the NF-κB pathway                     |
|                                            | Rb1                                      |                                | Upregulating the expression of proliferating cell nuclear antigen                   |
|                                            | Rb1                                      |                                | Inhibiting the transcription and activation of transforming growth factor-β1          |
| Targeting chronic kidney disease           | Rd                                       | Rats model reduced by cuniaterial ureteral obstruction | Preventing oxygen free radicals from attacking the cell membranes                    |
|                                            | Rb1                                      |                                | Reducing the levels of inflammatory factors TNF-a and 1L-6, and creatinine level     |
| Targeting diabetic kidney disease          | Rb1                                      | HGMC                           | Inhibiting the phosphorylation levels of P38 MAPK, JNK/SAPK and Akt                 |
|                                            | Rb1                                      |                                | reduce serum creatinine and urea nitrogen, mesangial hyperplasia of the glomerulus, and dilation of renal tubules |
| Targeting acute kidney injury              | Rb1                                      | Glycerol-induced acute renal failure | Activating heme oxygenase (HO-1), Nrf2, and reducing ROS peroxidation                 |
|                                            | Rb1                                      | Unilateral ureteral infarction in rats | Inhibit interstitial fibrous tissue, including tubular tissue damage and collagen deposition via reducing TGF-β1, HO-1 and 8-OHdG |
|                                            | Rb1                                      |                                | Downregulating the expression of Bcl-2 and Bax to inhibit apoptosis                 |
|                                            | Rb1                                      |                                | Reducing the content of MDA and increase the activity of SOD in renal tissue       |
| Targeting renal senescence                 | Rb1                                      | SAMP8 mice                     | Inhibiting the expression of the fibrinogen TGF-β1 and upregulating the renal protective factor BMP-7 |
| Targeting renal fibrosis                   | Rg1                                      | UUO animal models              | Decreasing a-SMA and E-cadherin expression in the obstructed kidney models and reduce TGF-β1 induced by rat tubular cells |
|                                            | Rg1                                      |                                | Reverse EMT and renal interstitial fibrosis via targeting the TGF-β1/Smad pathway |
|                                            | Ginseng extract                          | Cyclosporine A animal models; HK-2 cells | Improve renal function and inhibit apoptotic cell death                              |
|                                            | Ginseng extract                          |                                | Targeting the Akt/mTOR pathway                                                     |
|                                            | Ginsenosides                             | Diabetic nephropathy rats      | Protect kidney function via enhancing SIRT1 and suppressing inflammation             |
changes in podocyte protein expression and reorganization of the actin cytoskeleton (Fan et al., 2021). Panax notoginseng is the main active ingredient of Panax notoginseng (Burkill) F.H.Chen including Ginsenoside, (Rg1, Rg2, Rb1, Rb2, Rb3, Rc, Rd, Re, Rh, F2), Panax notoginosides (R1, R2, R3, R6, Fa, Fc, Fe, R4). In recent years, the role of PNS in improving podocyte damage has received widespread attention. Sun et al. (2011) reported that in the STZ-induced Diabetic Nephropathy (DN) rat model and the podocyte cell model stimulated by high glucose, the podocyte apoptosis might be related to oxidative stress, and PNS can improve oxidative stress-related indicators in vivo and in vitro, as well as downregulate the expression of the apoptosis marker protein (caspase-3). In addition, Zhou et al. observed the protective effect of PNS on the podocytes of DN rat. The findings showed that after 10 weeks of PNS intervention, the number of podocytes, mRNA expression of nephrin, α3β1 integrin proteins in the kidney tissue have been significantly improved accordingly (Zhou et al., 2014). These studies demonstrate promising evidence that PNS can improve podocyte damage and delay the progression of DN.

**Protection of Glomerular Endothelial Barrier Function**

Over the past decade, the preponderance of evidence supports that Panax ginseng C.A.Mey. can improve vascular endothelial function in several diseases (Nabavi et al., 2015). The destruction of the endothelial barrier is critical for vascular complications related to diabetes, and damage to the endothelial glycocalyx has been shown to be involved in this process (Fu et al., 2015). Rg1 is the main active ingredient extracted from Panax notoginseng and has been widely used to prevent vascular damage. Recent research (Zhu et al., 2019) showed that high glucosceuland induce endothelial glycocalyx disorders and increase the expression of heparanase mRNA in HUVEC, and Rg1 treatment can reverse this expression. In addition, after high glucose stimulation, Rg1 treatment can reduce transendothelial resistance and transendothelial albumin pass rate. It is worth noting that Rg1 has a protective effect on endothelial barrier dysfunction.

**Inhibition Apoptosis of Glomerular Mesangial Cells**

Glomerular mesangial cells (MCs) are major components of the glomerular mesangium, hold the capillary arteries and connect them with the juxtaglomerular apparatus. More and more evidences are suggesting the abnormal growth of MCs is an early event in various glomerular diseases (Yoon et al., 2020; Wan et al., 2021). Targeting glomerular mesangial cells as the research object and screening for suitable drugs to repair the damage caused by oxidative stress and inflammation have...
important scientific research significance and clinical value. Rg1 has been demonstrated to have a wide range of pharmacological properties, such as anti-inflammatory, anti-oxidation, anti-ageing, anti-fatigue and anti-tumour activities (Shen et al., 2017; Fan et al., 2020b). Rg1 has an anti-inflammatory effect, and the anti-inflammatory effect may be related to the inhibition of the TGF-β1/Smad signaling pathway (Zhao, 2018). A certain concentration of ginsenoside Rg1 can inhibit glycosylation end products (AGEs) caused by TNF-α And cyclooxygenase-2 (COX-2) (Zhao, 2018). Notably, Rg1 can promote the proliferation of mesangial cells and inhibit cell apoptosis, which may be related to the promotion of Bcl-2 and the inhibition of Caspase-3 expression (Tang et al., 2013). Besides, in the oxidative stress injury model of human glomerular mesangial cells induced by H2O2, Rg 3 can reduce the number of apoptotic cells damaged by H2O2, the activity of extracellular lactate dehydrogenase (LDH), and the content of malondialdehyde (MDA) as well as block the cell cycle of human glomerular mesangial cells in G1 phase, and downregulate the mRNA and protein expression level of Cyclin-dependent kinase 4 (CDK4) (Wu and Wang, 2015). These evidences reflect that Rg1 exerts renal protection by inhibiting the apoptosis of mesangial glomerular cells.

Inhibition Epithelial-Mesenchymal Transdifferentiation of Renal Tubular Cells

Epithelial-mesenchymal transition (EMT) is a biological process that directs changes in cell states along the epithelial versus mesenchymal axes, which is a hallmark of tubulointerstitial renal fibrosis (Chen et al., 2020). In addition, the nuclear factor-KB (NF-KB) pathway mainly mediates the inflammatory response, which is associated with activation for phosphatidylinositol 3-kinase (PI3K) and serine/threonine kinase (Akt) pathway (Yang et al., 2019). These signal pathways play a key role in the EMT.

Evidence from several in vitro studies has suggested that Rg1 plays a positive role in improving EMT of renal tubular cells. Ni et al. found that ginsenoside Rg1 protects the human renal tubular epithelial cell line HK-2 from lipopolysaccharide (LPS)-induced inflammation and apoptosis via activating the PI3K/AKT pathway and inhibiting the NF-KB pathway, thereby inhibiting the EMT in renal tubular cells (Ni et al., 2017). This result was confirmed by Yang et al. They used urine protein to induce renal tubular epithelial cell damage and reduce the cell survival rate. After administration of Rg 1, the cell survival rate was improved. And the expression of proliferating cell nuclear antigen (PCNA) protein and PCNA mRNA were upregulated (Yang et al., 2015). The results from the in vitro studies were confirmed using an in vivo model. In a rat model of renal interstitial fibrosis induced by unilateral ureteral obstruction (UOO), Rg1 inhibits the transcription and activation of transforming growth factor-β1 (TGF-β1) and inhibits the transdifferentiation of tubular epithelial myofibroblast (Tubular epithelial myofibroblast transdifferentiation, TEMT) (Xie et al., 2008; Li et al., 2015a). These data provided evidence that the tubular epithelial cells were responding to Rg1 treating EMT.

ROLE OF PANAX GINSENG C.A.MEY. IN DIFFERENT NEPHROPATHY

Kidney diseases worldwide prevalence have reached epidemic proportions globally in the last few decades. Several drugs that provide kidney function protection have been widely used. Unfortunately, drug resistance and adverse events have limited their applicability in the clinic. Recently, Panax ginseng C.A.Mey. and Panax ginseng C.A.Mey. extracts have attracted much attention as effective and safe alternative drugs for kidney diseases. Here, we will comprehensively summarize the current studies of Panax ginseng C.A.Mey. in different kidney diseases.

Chronic Kidney Disease

Chronic Kidney Disease (CKD) usually has concealed onset and gets progressively worse, followed by an increasing burden of hypertension, atherosclerosis, calcium and phosphorus metabolism disorders, renal anaemia and other complications, which is a cause of substantial healthcare expenditure (Chen et al., 2019; Tonelli and Dickinson, 2020). Oxidative stress is known as the main mechanism of CKD, and antioxidants have potential value in the treatment of CKD (Podkowińska and Formanowicz, 2020). Most studies have proved that ginsenosides have good anti-oxidation and free radical scavenging functions in vivo and in vitro (Jung et al., 1998; Kim et al., 2000; Kim et al., 2013). Some scholars investigated the effect of Rd in rats with ischemia-reperfusion. Findings indicate that ginsenoside-Rd could affect cultured proximal tubule cells subjected to hypoxia-reoxygenation, probably by preventing oxygen free radicals from attacking the cell membranes (Yokozawa et al., 1998). This was demonstrated in a preliminary clinical trial by Xu et al. CKD patients on oral Rb1 (500 mg) were found to be more likely to have a lower level of creatinine than among those on the placebo group. Additionally, compared with the placebo group, the of the active Oxygen is significantly improved, and the levels of inflammatory factors TNF-a and IL-6 are significantly reduced in the Rb1 group (Xu et al., 2017).

Diabetic Kidney Disease

Diabetic kidney disease (DKD) is one of the common and serious long-term complications of hyperglycemia, and long-term glucose metabolic disorder is the main cause of DKD (Barrera-Chimal and Jaisser, 2020). The clinical manifestations are reduced glomerular filtration rate, followed by microalbuminuria, elevated arterial blood pressure, and fluid retention, leading to renal failure (Matoba et al., 2019). In the primary mesangial cell model induced by high glucose, it was found that ginsenoside Rb1 mainly inhibited the phosphorylation levels of p38 MAPK, JNK/SAPK and Akt, and thus suppressed the expression of mesangial fibroconnectin induced by high glucose (Park et al., 2010). At animal levels, Rb1 can improve the quality of life of diabetic nephropathy induced by streptozotocin in rats, reduce serum creatinine and urea nitrogen, mesangial hyperplasia of
the glomerulus, and dilatation of renal tubules, mainly via down-regulating mRNA and protein expression of MCP-1 mRNA and TGF-β1 mRNA in kidney tissue (Zhao et al., 2008; Zhang et al., 2008; Koizumi et al., 2013). In addition, clinically, strict glycaemia and blood pressure control can also slow the progression of DKD (Doshi and Friedman, 2017). Panax ginseng C.A.Mey. plays an important role in the improvement of hypertension, hyperglycaemia and lipid metabolism disorders. Rb1 can reduce the complications of diabetic nephropathy by reducing free fatty acids, promoting lipid metabolism, improving insulin resistance in obese mice, inhibiting the levels of TNF-α and IL-6 inflammatory factors, and the decomposition of adipocytes (Wang, 2011). Ginsenosides (Rg1, Rg3, Rb1 and compound K) act on the targets of Caspase-3, Bel-2, MDA, and SOD, reducing the gluconeogenesis, lipid metabolism, inflammatory and oxidation in diabetic nephropathy, which can be used as a potential adjunctive drug for the treatment of diabetes (Bai et al., 2018; Shao et al., 2020).

**Acute Kidney Injury**

Acute kidney injury (AKI) is a common clinical critical illness, mainly manifested as the accumulation of metabolic substances and declined renal functions (Guo et al., 2019a). Renal ischemia and reperfusion injury (IRI) is a major cause of acute kidney injury (AKI) (Singbartl and Kellum, 2012). Ginsenosides are reported to have antioxidant and anti-inflammatory effects, as well as remit kidney damage caused by intestinal ischemia in mice. Rb1 can activate heme oxygenase (HO-1), Nrf2, and reduce ROS peroxidation damages and protect mitochondrial function to reduce kidney damages (Sun et al., 2013; Sun, 2014). In acute kidney injury mediated by unilateral ureteral infarction in rats, Rb1 can significantly inhibit interstitial fibrous tissue, including tubular tissue damage and collagen deposition via reducing TGF-β1, HO-1, and 8-OHdG (Xie et al., 2009a). In the renal artery ischemia of white rabbits, Rb1 can downregulate the expression of Bel-2 and Bax to inhibit apoptosis and reduce kidney damage (Zhu et al., 2009). Similarly, Sun et al. found that Rb1 can reduce the content of MDA and increase the activity of SOD in renal tissue, and then downregulate the expression of Caspase-3 in renal cells, thus alleviating the apoptosis of renal cells induced by ischemia and reperfusion to protect the kidney function (Sun et al., 2018).

**Renal Senescence**

Progressive renal recession is a common phenomenon in the ageing process, and ageing-related declines in renal function are associated with a progressive loss of functioning nephrons (Fang et al., 2020). Glomerular basement membrane thickening, mesangial matrix hyperplasia, segmental glomerulosclerosis, renal tubular atrophy and tubulointerstitial fibrosis, arterial intimal fibrous thickening are the main histological features of renal ageing (Docherty et al., 2019). Ginsenoside Rbl can inhibit the expression of the fibrinogen TGF-β1 and upregulate the renal protective factor BMP-7 to reduce the abnormal accumulation of ECM components in the process of renal ageing, thereby harnessing tubular interstitial damage and glomerular sclerosis in the kidney ageing in SAMP8 mice (Docherty et al., 2019).

**Renal Fibrosis**

Chronic kidney disease, as a global public health burden, has attracted great attention. So far, it has faced huge challenges due to the lack of effective treatment strategies (Yang et al., 2020). Renal fibrosis is an important pathological process from chronic kidney disease to end-stage renal diseases (Humphreys, 2018). Ginsenosides have shown to exert a renoprotective effect. Findings from Xie et al. showed that ginsenoside Rg1 could retard interstitial fibrosis in the UUO animal models (Xie et al., 2008). Intriguingly, Rg1 also was reported that Rg1 could decrease a-SMA and E-cadherin expression in the obstructed kidney models and reduce TGF-β1 induced by rat tubular cells, hinting that the potential mechanism might be partly related to the kickbacking of EMT (Xie et al., 2008; Xie et al., 2009b; Li et al., 2015a). Besides this, their results showed that Rg1 could reverse EMT and UUO-induced renal interstitial fibrosis via targeting the TGF-β1/Smad pathway (Li et al., 2018).

As a commonly used clinical immunosuppressant, cyclosporine A (CsA) has been widely prescribed for inhibiting rejection after organ transplantation. Many experimental studies showed that long-term use of CsA could contribute to progressive renal interstitial fibrosis, renal cell apoptosis, and immune cell infiltration (Wu et al., 2018; Lin et al., 2019). Findings from Doh’s group showed that Panax ginseng C.A.Mey. extract could effectively improve renal function and inhibit apoptotic cell death in vivo and vitro (Doh et al., 2013; Liu et al., 2015). Meanwhile, the Akt/mTOR pathway participating in Panax ginseng C.A.Mey. extract for the CsA animal model has been identified, which might be involved in autophagosome formation and autophagic aggregates (Lim et al., 2014). In diabetic nephropathy rats, the protective role of ginsenosides on diabetic nephropathy was also verified in vivo experiments. Du et al. suggested that Panax ginseng C.A.Mey. administration could protect kidney function via enhancing SIRT1 and suppressing inflammation in diabetic nephropathy rats (Du et al., 2016). In light of the above, ginsenosides were suggested as an important option during the treatment of renal fibrosis.

**PANAX GINSENG C.A.MEY. FOR KIDNEY-RELATED DISEASES IN CLINICAL TRIALS**

In recent years, accumulating evidence has revealed that Panax ginseng C.A.Mey. has beneficial effects against diabetes, obesity, stroke, and cardiovascular diseases (Kim, 2012; Rastogi et al., 2014; Zhang et al., 2014; Gu et al., 2016; Hong et al., 2020). However, fewer data are available in the field of Panax ginseng C.A.Mey. for kidney-related diseases in clinical trials. Here, we summarized this topic while adding some important updates and focused on the clinical trials of kidney-related diseases. Li et al. implemented a randomized
single-blinded trial with an administration of American Panax ginseng C.A.Mey. compound liquor or American Panax ginseng C.A.Mey. liquor. Their results showed that Panax ginseng C.A.Mey was beneficial to improve microcirculation, reduce whole blood viscosity and decrease urinary albumin so as to retard the progress of DKD (Lang et al., 1998). The results agreed with the findings of CKD patients from Peng and Guo (2010) and Xu et al. (2017). Peng et al. focused on the Panax notoPanax ginseng C.A.Mey. for chronic renal failure (CRF), which the study showed that Panax notoPanax ginseng C.A.Mey. possessed such therapeutic effects as improving the renal function and lowering urine protein (Peng and Guo, 2010). The aim of Xu et al. study (Xu et al., 2017) was to evaluate the effects of Rb1 (500 mg daily oral administration) prospectively in patients with early CKD (stage 2 or 3) for 6 months. Findings showed that GS-Rb1 could present an antioxidant-based approach to slow the progression of CKD at the early stages (Xu et al., 2017). However, some studies concluded the opposite (Stavro et al., 2006; Kulaputana et al., 2007). Panax ginseng C.A.Mey. did not affect serum cystatin C level, 24-h BP and renal function (Stavro et al., 2006), as well as an ergogenic property on aerobic fitness enhancement in well-fit individuals (Kulaputana et al., 2007). The conflicting evidence outlined above might be due to the poor research quality employed. The reason can attribute to the following reasons: 1) the sample size of these studies was relatively small and results in weak statistical power. 2) patients with CKD form heterogeneous study populations, so that it may be more difficult to control for confounding. Especially, DKD population is highly heterogeneous in terms of comorbid illnesses and functional impairments. 3) Under population heterogeneity, selection of the features that affect the drug sensitivity has not been addressed in trials. These factors may have contributed to the inconsistency of these findings.

LIMITATIONS AND FUTURE PERSPECTIVES

Ginsenosides as natural medicine have been widely approved to exert therapeutic effects in kidney-related in vivo and vitro. However, human clinical studies present several limitations. There are several existing obstacles concerning the utilization of ginsenosides or Panax ginseng C.A.Mey. before translation into clinical application is made possible. One of the most difficult handicaps is a lack of high-quality, evidence-based medical evidence for Panax ginseng C.A.Mey. treating kidney-related diseases. In respect of study population selection, the current research is still insufficient due to the focusing on a single participant (such as DKD, CKD); thus, further exploration (such as IgA nephropathy, Kidney ageing) is required. In terms of the selection of the indicators, the current study focuses on more serum creatinine levels, proteinuria, urea nitrogen, and physiological and biochemical parameters, less than estimated glomerular filtration rate (eGFR), urine albumin-creatinine ratio (UACR) and the composite of renal outcomes (annual rate of change in GFR, doubling of serum creatinine level or 50% reduction in GFR, end-stage renal disease).

In addition, CKD may have electrolyte abnormalities, proteinuria, and anemia. It is a key role to control these risk factors. However, there is currently a lack of evidence to support that. Future CKD should focus not only on the inherent cells but also on the electrolyte abnormalities, proteinuria, and anemia. Although creatinine levels, proteinuria, urea nitrogen, and physiologic and biochemical parameters could reflect renal functions in part, these outcomes might not show a replaceable role in the progression of renal diseases (Luo et al., 2019; Kurth et al., 2020). Therefore, evaluating the composite of renal outcomes in clinical trials is a future direction for researchers. Performing well-designed, randomized, placebo-controlled clinical trials for ginsenosides in humans are very urgent and pivotal.

Furthermore, oral bioavailability has been reported to affect the efficacy of some drugs. It has been demonstrated that the majority of ginsenosides had low oral bioavailability, which limits their long-term efficacy and stability (Kim et al., 2014; Biswas et al., 2017; Chen et al., 2018; Jin et al., 2018). Some scholars tend to explain the factors that lead to low oral bioavailability of ginsenosides, which large molecular weight (Han et al., 2006), low water-solubility (Liu et al., 2009), poor gastrointestinal stability of ginsenosides (Artursson et al., 1993), and intestinal or hepatic first-pass effect, then leading to low oral bioavailability (Yanni, 2007). Future studies should address these issues to fully determine the bioavailability of ginsenosides via building effective drug delivery systems, including vesicles (Chen et al., 2014), microsphere (Wei et al., 2007), micelles (Xiong et al., 2008), emulsion delivery systems (Li et al., 2015b), and nanoparticle drug delivery systems (Cai et al., 2014).

The safety of Panax ginseng C.A.Mey. in clinical practices is an issue of widespread concern. Although the efficacy and safety of Panax ginseng C.A.Mey. or ginsenosides have been confirmed in these clinical trials in Table X, the safety should be evaluated with caution due to the low quality and quantity of research. Moreover, natural products are the basis of traditional Chinese medicine, which the most biological function is entirely by identifying their pharmacologically active ingredients. Hence, it is difficult to ensure safety (Li et al., 2020a). In clinical applications, possible side effects need much-weighted attention.

Evidence that ginsenosides have significant effects on antioxidative, anti-inflammatory, anti-apoptotic, and anti-fibrosis, with different molecular mechanisms. These processes participate in the regulation of physiological and pathological conditions and are implicated in kidney disease development (Kim et al., 2019; Knoppert et al., 2019; Alicic et al., 2021). However, a comprehensive understanding of the mechanisms that ginsenosides regulate in diverse pathological conditions is lacking. Additionally, more in-depth research should explore the detailed molecular mechanisms of action and pharmacokinetic profile in vivo. Careful study will be required to resolve these issues in the future.
CONCLUSION

In this work, we summarize brief information on diverse types of studies in vitro and vivo concerning kidney diseases that suggest similar pathological mechanisms, including inflammatory response, apoptosis of innate renal cells, vascular endothelial function, renal senescence, and renal fibrosis. These pathological processes have been identified, all of which might be influenced by ginsenosides. In clinical applications, its efficacy has been demonstrated in several clinical trials. As an advantage to anti-inflammatory, ginsenosides can improve glomerular endothelial barrier function; alleviate the apoptosis of renal cells induced by ischemia and reperfusion to protect the kidney function in AKI; inhibit the excessive accumulation of ECM, including collagen and fibronectin as well as fibrotic markers, especially TGF-β1 in renal tubular cells; inhibit apoptosis of glomerular mesangial cells; decrease the damage to podocyte cells, including apoptotic and necrotic changes. Ginsenosides exert their kidney-protected effects in the kidney (Figure 3). Collectively, ginsenosides are capable of being a remedy for kidney protection.

Effective therapeutics is currently available for this situation in several clinical trials. However, most of these studies reported contradictory or conflicting findings because of low methodological quality. For this reason, strong evidence is still needed to solve this issue, such as RCTs of rigorous trial design methods and a large, multicenter sample. Moreover, abundant studies have repetitively revealed the therapeutic potential of ginsenosides in kidney-associated human diseases. Meanwhile, new guidelines about Panax ginseng C.A.Mey. usage are imperative to guarantee safety and effectiveness, which is vital for standardized operation practice and experimentally controlled methods. This review provides the first systematic summary of studies examining the role of kidney protection, which will be helpful in the development of kidney-related diseases therapy in the future and gain more reliable and reproducible data.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

We thank the National Administration of Traditional Chinese Medicine for supporting this work. This work was supported by a 2015 Traditional Chinese Medicine Scientific Research grant (No. 201507001-11).
REFERENCES

Alaoui, A. L. (2020). Sinapic Acid Ameliorates the Progression of Streptozocin (STZ)-Induced Diabetic Nephropathy in Rats via NRF2/HO-1 Mediated Pathways. *Front. Pharmacol.* 11, 1119. doi:10.3389/fphar.2020.01119

Alicic, R. Z., Cox, E. J., Neumiller, J. J., and Tuttle, K. R. (2021). Incretin Drugs in Diabetic Kidney Disease: Biological Mechanisms and Clinical Evidence. *Nat. Rev. Nephrol.* 17, 227–244. doi:10.1038/s41581-020-00367-2

Artursson, P., Ungell, A. L., and Lofroth, J. E. (1993). Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments. *Pharmacol. Res.* 10, 1123–1129. doi:10.1016/1043-6618(93)903177

Bai, L., Gao, J., Wei, F., Zhao, J., Wang, D., and Wei, J. (2018). Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes. *Front. Pharmacol.* 9, 423. doi:10.3389/fphar.2018.00423

Barrera-Chimal, J., and Jaisser, F. (2020). Pathophysiologic Mechanisms in the Ageing Kidney: Molecular Mechanisms and Clinical Implications. *Aging Res. Rev.* 63, 101151. doi:10.1016/j.arr.2020.101151

Fu, J., Lee, K., Chuang, P. Y., Liu, Z., and He, J. C. (2015). Glomerular Endothelial Cell Injury and Cross Talk in Diabetic Kidney Disease. *Am. J. Physiol. Ren. Physiol.* 308, F287–F297. doi:10.1152/ajprenal.00533.2014

Gu, Q. F., Xu, Z. R., Xu, K. Y., and Yang, Y. M. (2016). The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis. *Medicine (Baltimore)* 95, e2584. doi:10.1097/MD.0000000000002584

Guo, C., Dong, G., Liang, X., and Dong, Z. (2019a). Epigenetic Regulation in AKI and Kidney Repair: Mechanisms and Therapeutic Implications. *Nat. Rev. Nephrol.* 15, 220–239. doi:10.1038/s41581-018-01036-3

Guo, X., Zhang, J., Liu, M., and Zhao, G. C. (2019b). Protective Effect of Ginsenoside Rgl1 on Attenuating Anti-GBM Glomerular Nephritis by Activating NRF2 Signalling. *Artif. Cell Nanomed. Biotechnol.* 47, 2972–2979. doi:10.1016/j.1616-9033.2019.140672

Han, M., Sha, X., Wu, Y., and Fang, X. (2006). Oral Absorption of Ginsenoside Rb1 Using *In Vitro* and *In Vivo* Models. *Planta Med.* 72, 398–404. doi:10.1055/s-2005-916211

Hong, S. H., Hwang, H. J., Kim, J. W., Kim, J. A., Lee, Y. B., Roh, E., et al. (2020). Ginsenoside Compound-Mc1 Attenuates Oxidative Stress and Apoptosis in Cardiomyocytes through an AMP-Activated Protein Kinase-dependent Mechanism. *J. Ginseng Res.* 44, 664–671. doi:10.1016/j.jgr.2019.08.006

Huang, Q., Zhang, H., Bai, L. P., Law, B. Y. K., Xiong, H., Zhou, X., et al. (2020). Novel Ginsenoside Derivative 20(S)-Rg2E2 Suppresses Tumor Growth and Metastasis *In Vivo* and *In Vitro* via Intervention of Cancer Cell Energy Metabolism. *Cell Death Dis.* 11, 621. doi:10.1038/s41419-020-02881-4

Humphreys, B. D. (2018). Mechanisms of Renal Fibrosis. *Annu. Rev. Physiol.* 80, 309–326. doi:10.1146/annurev-physiol-022516-034227

Jang, M., Choi, I. H., Chang, Y., Lee, S. J., Nah, S. Y., and Cho, I. H. (2019). Cinnitinon, a Ginseng-Derived Ingredient, as a Novel Therapeutic Strategy for Huntington’s Disease: Activation of the Nrf2 Pathway through Lysophosphatidic Acid Receptors. *Brain Behav. Immun.* 80, 146–162. doi:10.1016/j.bbi.2019.03.001

Jin, Z. H., Qiu, W., Liu, H., Jiang, X. H., and Wang, L. (2018). Enhancement of Oral Bioavailability and Immune Response of Ginsenoside Rg2 by Co-administration with Piperine. *Chin. J. Nat. Med.* 16, 143–149. doi:10.3391/cjnm.2018.5-18

Jung, K. Y., Kim, D. S., Oh, S. R., Lee, I. S., Lee, J. J., Park, J. D., et al. (1998). Platelet Activating Factor Antagonist Activity of Ginsenosides. *Biochem. Pharm.* 21, 79–80. doi:10.1248/bph.21.79

Kalluri, R. (2003). Basement Membranes: Structure, Assembly and Role in Tumour Angiogenesis. *Nat. Rev. Cancer* 3, 422–433. doi:10.1038/nrc1094

Kim, W. Y., Kim, J. M., Han, S. B., Lee, S. K., Kim, D. N., Park, M. K., et al. (2000). Steaming of Ginseng at High Temperature Enhances Biological Activity. *J. Nat. Prod.* 63, 1702–1704. doi:10.1021/np990152b

Kim, E. J., Oh, H. A., Choi, H. J., Park, J. H., Kim, D. H., and Kim, N. J. (2013). Heat-processed Ginseng Saponin Ameliorates the Adenine-Induced Renal Failure in Rats. *J. Ginseng Res.* 37, 87–93. doi:10.5142/jgr.2013.37.87

Kim, E. O., Cha, K. H., Lee, E. H., Kim, S. M., Choi, S. W., Pan, C. H., et al. (2014). Bioavailability of Ginsenosides from white and Red Ginsengs in the Simulated Digestion Models. *Agric. Food Chem.* 62, 10055–10063. doi:10.1021/acs.jafc.1400477

Kim, Y. G., Kim, S.-M., Kim, K.-P., Lee, S.-H., and Moon, J.-Y. (2019). The Role of Inflammasome-dependent and Inflammasome-independent NLRP3 in the Kidney. *Cells* 8, 1389. doi:10.3390/cells8111389

Kim, J. H. (2012). Cardiovascular Diseases and Panax Ginseng: A Review on Molecular Mechanisms and Medical Applications. *J. Ginseng Res.* 36, 16–26. doi:10.5142/jgr.2012.36.26.16

Kongpoot, S. N., Valentin, F. A., Nguyen, T. Q., Goldschmeding, R., and Falke, L. L. (2019). Cellular Senescence and the Kidney: Potential Therapeutic Targets and Tools. *Front. Pharmacol.* 10, 770. doi:10.3389/fphar.2019.00770

Koizumi, S., Ohsawa, K., Inoue, K., and Kohsaka, S. (2013). Purinergic Receptors in Renal Tubular Cells and Glomerular Endothelial Cells in Diabetic Kidney Disease. *J. Am. Soc. Nephrol.* 24, 53, e12763. doi:10.1681/ASN.2019.12.12763

Koch, Q. F., Xu, Z. R., Xu, K. Y., and Yang, Y. M. (2016). The Efficacy of Ginseng-Related Therapies in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis. *Medicine (Baltimore)* 95, e2584. doi:10.1097/MD.0000000000002584

Koizumi, S., Ohsawa, K., Inoue, K., and Kohsaka, S. (2013). Purinergic Receptors in Renal Tubular Cells and Glomerular Endothelial Cells in Diabetic Kidney Disease. *J. Am. Soc. Nephrol.* 24, 53, e12763. doi:10.1681/ASN.2019.12.12763

Podocytes. *Cells* 53, e12763. doi:10.1111/cpr.12763
Tang, X. Y., Liu, G. L., Xia, Z. K., and Xu, H. Q. (2013). Effect of Ginsenoside Rg1 on Dextran-Induced Apoptosis of Mesangial Cell. *Mod. Med.* (4), 226–231. doi:10.3969/j.issn.1671-7562.2013.04.002

Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A., Zoungas, S., et al. (2015). Diabetic Kidney Disease. *Nat. Rev. Dis. Primers* 1, 15018. doi:10.1038/nrdp.2015.18

Tonelli, M., and Dickinson, J. A. (2020). Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries. *J. Am. Soc. Nephrol.* 31, 1931–1940. doi:10.1681/ASN.2020030277

Wan, S., Wang, S., Jiao, X., Cao, H., Gu, Y., Yan, L., et al. (2021). Advances in Understanding the Innate Immune-Associated Diabetic Kidney Disease. *FASEB J.* 35, e21367. doi:10.1096/fj.202022334R

Wang, G. Q. (2011). Evaluation of the Antidiabetic Effect of Ginsenoside RBl Based on FFA Spillover of Adipocytes. *Jiangsu University of Traditional Chinese Medicine.* do:10.7666/dy1945370

Webster, A. C., Nagler, E. V., Morton, R. L., and Masson, P. (2017). Chronic Kidney Disease. *Lancet* 389, 1238–1252. doi:10.1016/S0140-6736(16)32064-5

Wei, H. J., Yang, H. H., Chen, C. H., Lin, W. W., Chen, S. C., Lai, P. H., et al. (2007). Gelatin Microspheres Encapsulated with a Nonpeptide Angiogenic Agent, Ginsenoside Rgl, for Intramyocardial Injection in a Rat Model with Infarcted Myocardium. *J. Control. Release* 120, 27–34. doi:10.1016/j.jconrel.2007.04.005

Wong, A. S., Che, C. M., and Leung, K. W. (2015). Recent Advances in Ginseng as Medicine in Pharmacology and the Incorporation of Lipid in the Formulation Affect the Intestinal Absorption of Ginseng Pectins on Galectin-3-Mediated T Cell Activation and Apoptosis. *Drug Des. Devel Ther.* 32, 256–272. doi:10.2147/DDDT.S200204

Xue, H., Zhao, Z., Lin, Z., Geng, J., Guan, Y., Song, C., et al. (2019). Selective Effects of Ginseng Proliferation Inhibitory Effect on Malignant Melanoma Cells. *Drug Dev. Devel Ther.* 15, 133–140. doi:10.1186/s12986-019-0133-9

Yoon, J. J., Lee, H. K., Kim, H. Y., Han, B. H., Lee, H. S., Lee, Y. J., et al. (2020). Sauchinone Protects Renal Mesangial Cell Dysfunction against Angiotensin II by Improving Renal Fibrosis and Inflammation. *Int. J. Mol. Sci.* 21, 7003. doi:10.3390/ijms21197903

Zhang, X. K., Zhao, Z. J., Cui, X. M., Zhang, X. X., and Yang, M. J. (2008). Effect of Ginsenoside-Rg1 and Rb1 on the Kidney and Renal Expression of MCP-1 mRNA and Protein in Rat Model with Diabetic Nephropathy. *Chin. J. Integr. Tradit. West. Med.* 9 (7), 578–581. doi:10.3969/j.issn.1009-587X.2008.07.005

Zhang, Y., Yu, L., Cai, W., Fan, S., Feng, L., Ji, G., et al. (2014). Protopanaxatriol, a Novel PPARγ Antagonist from Panax Ginseng, Alleviates Steatosis in Mice. *Sci. Rep.* 4, 7375. doi:10.1038/srep07375

Zhu, M. X., Ran, B., Feng, Z. Q., and Pan, Q. W. (2009). Effects of Rb1 and Rg1 on the Expression of TGFβ-1Smad Signaling Pathway. *China Pharmacist* 21 (11), 1919–1923. doi:10.3232/j.issn.1673-4254.2007.07.037 Available at: http://www.cnki.com.cn/Article/CFJDTOTAL-ZYSG201101007.htm (Accessed May 25, 2021).

Zhao, J. J., Ai, Z. M., Sun, W., Wu, L. L., Qin, L., Ji, L., et al. (2014). Mechanism Study of Panax Notoginseng Saponins on Protective Effect for Podocyte in Diabetic Nephropathy Mice. *China J. Tradit. Chin. Med. Pharm.* 29 (05), 1316–1321. Available at: http://med.wansfangdata.com.cn/PaperDetail?id=PeriodicalPaper_zgyyxb201105039. (Accessed May 21, 2021).

Zhao, J. (2018). Effects of Ginsenoside Rg1 on Glomerular Mesangial Cell Inflammation Induced by Glycosylation End Products and TGFβ/Smad Signaling Pathway. *J. Beijing Univ. Tradit. Chin. Med.* 34, 597–602. doi:10.7501/j.issn.1674-5515.2015.12.002

Zhou, J. X., Ai, Z. M., Sun, W., Wu, L. L., Qin, L., Ji, L., et al. (2014). Mechanism Study of Panax Notoginseng Saponins on Protective Effect for Podocyte in Diabetic Nephropathy Mice. *China J. Tradit. Chin. Med. Pharm.* 29 (05), 1316–1321. Available at: http://med.wansfangdata.com.cn/PaperDetail?id=PeriodicalPaper_zgyyxb201105039. (Accessed May 21, 2021).

Zhu, X. M., Ran, B., Feng, Z. Q., and Pan, Q. W. (2009). Effects of Rb1 and Rg1 on the Expression of Bcl-2, Bax in Apoptosis of HK-2 Cells Induced by the Serum of Kidney Ischemia/reperfusion. *Zhuangguo Ying Yong Sheng Li Xue Za Zhi* 25, 496–499.

Zhu, T., Fang, Y., Zheng, L., Huang, J., Cai, Y., and Ding, X. (2018). Protective Effect of Ginsenoside Rg5 against Kidney Injury via Inhibition of NLRP3 Inflammasome Activation and the MAPK Signaling Pathway in High-Fat Diet/streptozotocin-Induced Diabetic Mice. *Pharmacol. Res.* 135, 104746. doi:10.1016/j.phrs.2020.10.0476

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Jin, Zhang, Zhang, Duan, Zhou, Duan, Sun, Lian and Tong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.